| Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. | |
| | |
MedLine Citation:
|
PMID: 10099909 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Reteplase has been reported to achieve better patency of the infarct artery than alteplase. As infarct artery patency is strongly associated with survival among patients with cardiogenic shock, we postulated that treatment with reteplase would improve outcomes among shock patients. METHODS: We compared 30-day mortality rates among patients in GUSTO-III who either presented with shock or developed shock after enrollment; all patients received either front-loaded alteplase or reteplase (two bolus doses of 10 MU, 30 min apart). RESULTS: Shock occurred in 260 (5.3%) of 4921 patients randomized to alteplase and 560 (5.5%) of 10,138 patients randomized to reteplase. Of these patients, 28 (10.8%) and 55 (9.8%) randomized to alteplase and reteplase, respectively, presented with shock. In-hospital, 35% and 37% of shock patients assigned to alteplase or reteplase, respectively, underwent coronary angiography, with similar rates of percutaneous (approximately 11-13%) or surgical (approximately 2-3%) revascularization procedures subsequently performed. Death within 30 days occurred in 169 (65%) and 353 (63%) shock patients randomized to alteplase and reteplase, respectively (P = 0.59). Of patients presenting with shock, 64% and 58% of patients randomized to alteplase or reteplase died within 30 days (P = 0.59). CONCLUSION: Compared with alteplase, reteplase did not improve outcome among patients who presented with shock or developed shock after receiving thrombolytics. The newer-generation thrombolytic agents remain of limited efficacy in the treatment and prevention of shock. |
| | |
Authors:
|
D Hasdai; D R Holmes; E J Topol; P B Berger; D A Criger; J S Hochman; E R Bates; A Vahanian; P W Armstrong; R Wilcox; E M Ohman; R M Califf |
Related Documents
:
|
16278569 - Patients with epilepsy: a high-risk population prone to severe burns as a consequence o... 17925639 - Electrical burns in chinese fishermen using graphite rods under high-voltage cables. 7089649 - Septic shock and the obstetrician/gynecologist. 1845929 - Effects of granulocyte-macrophage colony-stimulating factor in burn patients. 982249 - Impaired glucose flow in burned patients with gram-negative sepsis. 22397469 - Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chro... 22595389 - The prevalence of peripheral neuropathy in hemodialysis patients. 3922219 - Serum lactate dehydrogenase levels in adults and children with acquired immune deficien... 11261329 - Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pil... |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Meta-Analysis; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European heart journal Volume: 20 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 1999 Jan |
Date Detail:
|
Created Date: 1999-05-20 Completed Date: 1999-05-20 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 128-35 Citation Subset: IM |
Affiliation:
|
Mayo Clinic, Rochester, MN 55905, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Chi-Square Distribution Female Fibrinolytic Agents / administration & dosage* Follow-Up Studies Humans Incidence Logistic Models Male Middle Aged Myocardial Infarction / complications, mortality, therapy* Plasminogen Activators / administration & dosage* Recombinant Proteins / administration & dosage Shock, Cardiogenic / drug therapy*, etiology, mortality* Statistics, Nonparametric Survival Rate Tissue Plasminogen Activator / administration & dosage* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 0/Recombinant Proteins; 133652-38-7/reteplase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator |
| Comments/Corrections | |
Comment In:
|
Eur Heart J. 1999 Jan;20(2):88-9
[PMID:
10099903
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. Th...
Next Document: Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of...